Risk factors for clostridium difficile toxin-positive diarrhea: A population-based prospective case-control study

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 31, Issue 10, 2012, Pages 2601-2610

  Vesteinsdottir, I ^a   Gudlaugsdottir, S ^b   Einarsdottir, R ^a   Kalaitzakis, E ^c   Sigurdardottir, O ^d   Bjornsson, E S ^a,b  

^a UNIVERSITY OF ICELAND   (Iceland)

^b LANDSPITALI UNIVERSITY HOSPITAL   (Iceland)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

^d Akureyri District Hospital   (Iceland)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTRIAXONE; CIPROFLOXACIN; CLINDAMYCIN; DICLOXACILLIN; METRONIDAZOLE; PROTON PUMP INHIBITOR; VANCOMYCIN;

ADULT; AGE; AGED; ARTICLE; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG UTILIZATION; FEMALE; HOME CARE; HOSPITALIZATION; HUMAN; ICELAND; INCIDENCE; MAJOR CLINICAL STUDY; MALE; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SEX RATIO; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BACTERIAL TOXINS; CASE-CONTROL STUDIES; CEFTRIAXONE; CHILD; CHILD, PRESCHOOL; CLINDAMYCIN; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; COMMUNITY-ACQUIRED INFECTIONS; CONFIDENCE INTERVALS; DIARRHEA; DICLOXACILLIN; ENTEROTOXINS; FEMALE; HUMANS; ICELAND; INCIDENCE; INFANT; LENGTH OF STAY; MALE; METRONIDAZOLE; MIDDLE AGED; ODDS RATIO; PROSPECTIVE STUDIES; PROTON PUMP INHIBITORS; RISK FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84869122095     PISSN: 09349723     EISSN: 14354373     Source Type: Journal    
DOI: 10.1007/s10096-012-1603-0     Document Type: Article

References (29)

1. Karlström O, Fryklund B, Tullus K, Burman LG (1998) A prospective nationwide study of Clostridium difficile-Associated diarrhea in Sweden. The Swedish C. difficile Study Group. Clin Infect Dis 26(1):141-145
2. Pépin J, Valiquette L, Alary ME, Villemure P, Pelletier A, Forget K, Pépin K, Chouinard D (2004) Clostridium difficile-Associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ 171(5):466-472
3. Elixhauser A, Jhung M (2008) Statistical brief #50. Clostridium difficile-Associated disease in U.S. Hospitals, 1993-2005. Available online at: http://www.hcup-us.ahrq.gov/reports/statbriefs/sb50.pdf
4. Kuijper EJ, Coignard B, Tüll P; ESCMID Study Group for Clostridium difficile; EU Member States; European Centre for Disease Prevention and Control (2006) Emergence of Clostridium difficileassociated disease in North America and Europe. Clin Microbiol Infect 12(Suppl 6):2-18
5. Pépin J, Valiquette L, Gagnon S, Routhier S, Brazeau I (2007) Outcomes of Clostridium difficile-Associated disease treated with metronidazole or vancomycin before and after the emergence of NAP1/027. Am J Gastroenterol 102(12):2781-2788
6. Jamal W, Rotimi VO, Brazier J, Duerden BI (2005) Analysis of prevalence, risk factors and molecular epidemiology of Clostridium difficile infection in Kuwait over a 3-Year period. Anaerobe 16 (6):560-565
7. Hensgens MP, Goorhuis A, van Kinschot CM, Crobach MJ, Harmanus C, Kuijper EJ (2011) Clostridium difficile infection in an endemic setting in the Netherlands. Eur J Clin Microbiol Infect Dis 30(4):587-593
8. Raveh D, Rabinowitz B, Breuer GS, Rudensky B, Yinnon AM (2006) Risk factors for Clostridium difficile toxin-positive nosocomial diarrhoea. Int J Antimicrob Agents 28(3):231-237
9. Sundram F, Guyot A, Carboo I, Green S, Lilaonitkul M, Scourfield A (2009) Clostridium difficile ribotypes 027 and 106: clinical outcomes and risk factors. J Hosp Infect 72(2):111-118
10. Al-Tureihi FI, Hassoun A, Wolf-Klein G, Isenberg H (2005) Albumin, length of stay, and proton pump inhibitors: key factors in Clostridium difficile-Associated disease in nursing home patients. J Am Med Dir Assoc 6(2):105-108
11. Pépin J, Saheb N, Coulombe MA, Alary ME, Corriveau MP, Authier S, Leblanc M, Rivard G, Bettez M, Primeau V, Nguyen M, Jacob CE, Lanthier L (2005) Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-Associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis 41(9):1254-1260
12. Howell MD, Novack V, Grgurich P, Soulliard D, Novack L, Pencina M, Talmor D (2010) Iatrogenic gastric acid suppression and the risk of nosocomial Clostridium difficile infection. Arch Intern Med 170(9):784-790
13. Kuntz JL, Chrischilles EA, Pendergast JF, Herwaldt LA, Polgreen PM (2011) Incidence of and risk factors for community-Associated Clostridium difficile infection: a nested case-control study. BMC Infect Dis 11:194
14. Fellmeth G, Yarlagadda S, Iyer S (2010) Epidemiology of community-onset Clostridium difficile infection in a community in the South of England. J Infect Public Health 3(3):118-123
15. Svenungsson B, Burman LG, Jalakas-Pörnull K, Lagergren A, Struwe J, Akerlund T (2003) Epidemiology and molecular characterization of Clostridium difficile strains from patients with diarrhea: low disease incidence and evidence of limited crossinfection in a Swedish teaching hospital. J Clin Microbiol 41 (9):4031-4037
16. Statistics Iceland (2011) Population. Available online at: http://www.statice.is/Statistics/Population
17. Ricciardi R, Rothenberger DA, Madoff RD, Baxter NN (2007) Increasing prevalence and severity of Clostridium difficile colitis in hospitalized patients in the United States. Arch Surg 142(7):624-631, discussion 631
18. Gravel D, Miller M, Simor A, Taylor G, Gardam M, McGeer A, Hutchinson J, Moore D, Kelly S, Boyd D, Mulvey M (2009) Health care-Associated Clostridium difficile infection in adults admitted to acute care hospitals in Canada: a Canadian Nosocomial Infection Surveillance Program Study. Clin Infect Dis 48(5):568-576
19. Kvaran RB, Valsdóttir EB, Sigurdsson HK, Gottfredsson M (2010) Clostridium difficile infections at Landspítali-1998-2008. Laeknabladid 96(9):523-529
20. Dubberke ER, Reske KA, Yan Y, Olsen MA, McDonald LC, Fraser VJ (2007) Clostridium difficile-Associated disease in asetting of endemicity: identification of novel risk factors. Clin Infect Dis 45(12):1543-1549
21. Wilcox MH, Mooney L, Bendall R, Settle CD, Fawley WN (2008) A case-control study of community-Associated Clostridium difficile infection. J Antimicrob Chemother 62(2):388-396
22. Bauer MP, Veenendaal D, Verhoef L, Bloembergen P, van Dissel JT, Kuijper EJ (2009) Clinical and microbiological characteristics of community-onset Clostridium difficile infection in The Netherlands. Clin Microbiol Infect 15(12):1087-1092
23. Bartlett JG (2002) Clinical practice. Antibiotic-Associated diarrhea. N Engl J Med 346(5):334-339
24. Loo VG, Poirier L, Miller MA, Oughton M, Libman MD, Michaud S, Bourgault AM, Nguyen T, Frenette C, Kelly M, Vibien A, Brassard P, Fenn S, Dewar K, Hudson TJ, Horn R, René P, Monczak Y, Dascal A (2005) A predominantly clonal multi-institutional outbreak of Clostridium difficile-Associated diarrhea with high morbidity and mortality. N Engl J Med 353(23):2442-2449
25. Kuijper EJ, van den Berg RJ, Debast S, Visser CE, Veenendaal D, Troelstra A, van der Kooi T, van den Hof S, Notermans DW (2006) Clostridium difficile ribotype 027, toxinotype III, the Netherlands. Emerg Infect Dis 12(5):827-830
26. Kuijper EJ, Barbut F, Brazier JS, Kleinkauf N, Eckmanns T, Lambert ML, Drudy D, Fitzpatrick F, Wiuff C, Brown DJ, Coia JE, Pituch H, Reichert P, Even J, Mossong J, Widmer AF, Olsen KE, Allerberger F, Notermans DW, Delmée M, Coignard B, Wilcox M, Patel B, Frei R, Nagy E, Bouza E, Marin M, Akerlund T, Virolainen-Julkunen A, Lyytikäinen O, Kotila S, Ingebretsen A, Smyth B, Rooney P, Poxton IR, Monnet DL (2008) Update of Clostridium difficile infection due to PCR ribotype 027 in Europe, 2008. Euro Surveill 13(31). pii: 18942
27. Bauer MP, Notermans DW, van Benthem BH, Brazier JS, Wilcox MH, Rupnik M, Monnet DL, van Dissel JT, Kuijper EJ; ECDIS Study Group (2011) Clostridium difficile infection in Europe: a hospital-based survey. Lancet 377(9759):63-73
28. Crobach MJ, Dekkers OM, Wilcox MH, Kuijper EJ (2009) European Society of Clinical Microbiology and Infectious Diseases (ESCMID): data review and recommendations for diagnosing Clostridium difficile-infection (CDI). Clin Microbiol Infect 15(12):1053-1066
29. Hensgens MP, Goorhuis A, Dekkers OM, Kuijper EJ (2011) Time interval of increased risk for Clostridium difficile infection after exposure to antibiotics. J Antimicrob Chemother 67(3):742-748